Novo Nordisk has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.

The US FDA has approved Ionis' TRYNGOLZA (olezarsen) as an adjunct to diet for reducing triglyceride levels in the adult population with FCS ...

The UK's DHSC has announced its anticipated 2025 headline payback rate for new medicines under the 2024–2028 VPAG.

Palleon and Henlius Biotech have entered into a licence agreement and partnership for the former’s E-602 to treat autoimmune diseases.

The US Food and Drug Administration (FDA) has stood by an earlier decision confirming that the tirzepatide shortage is over.

Astellas Pharma and Sangamo have signed a licence agreement for neurotropic adeno-associated virus (AAV) capsid, STAC-BBB.

BioAge Labs has entered a multi-year research partnership with Novartis to seek therapeutic drug targets for ageing-related conditions.

Picking the right clinical partners will be critical for oncology innovators hoping to stay up to speed in a rapidly changing industry.

Vertex said the Phase II trial met its primary endpoint, however there was only a minor difference to placebo.

Novo Holdings has completed the previously announced acquisition of Catalent in an all-cash transaction valued at around $16.5bn.

Abera and Orexo have entered a partnership to develop and test the powder formulations of the former’s vaccine candidates.

A new report identifies data content management as the primary driver of growth in the pharmaceuticals market.